Who are Florinef's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kerendia, Fludrocortisone/ Fludrocortisone acetate, Ambrisentan plus Spironolactone, Mineralocorticoid Receptor Antagonist, Finerenone (BAY 94-8862), ACEI / ARB+finerenone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fludrocortisone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Florinef — Competitive Intelligence Brief

Florinef (fludrocortisone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineralocorticoid. Area: Nephrology.

marketed Mineralocorticoid Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Florinef (fludrocortisone) — Generic.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Florinef TARGET	fludrocortisone	Generic	marketed	Mineralocorticoid	Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor	1954-01-01
Kerendia	FINERENONE	Bayer	marketed	Nonsteroidal Mineralocorticoid-Receptor Antagonist [EPC]	Mineralocorticoid receptor	2021-01-01
Fludrocortisone/ Fludrocortisone acetate	Fludrocortisone/ Fludrocortisone acetate	Merck Sharp & Dohme LLC	marketed	Mineralocorticoid receptor agonist; corticosteroid	Mineralocorticoid receptor (MR)
Ambrisentan plus Spironolactone	Ambrisentan plus Spironolactone	Brigham and Women's Hospital	marketed	Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination	Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor
Mineralocorticoid Receptor Antagonist	Mineralocorticoid Receptor Antagonist	Cheng-Hsin General Hospital	marketed	Mineralocorticoid receptor antagonist	Mineralocorticoid receptor (MR)
Finerenone (BAY 94-8862)	Finerenone (BAY 94-8862)	University Medical Center Groningen	marketed	Non-steroidal mineralocorticoid receptor antagonist	Mineralocorticoid receptor (MR)
ACEI / ARB+finerenone	ACEI / ARB+finerenone	Capital Institute of Pediatrics, China	marketed	ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination	Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineralocorticoid class)

Generic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Florinef — Competitive Intelligence Brief. https://druglandscape.com/ci/fludrocortisone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab